What’s in the Axial Spondyloarthritis Treatment Pipeline?
New treatments for axial spondyloarthritis (axSpA) are being developed to address the variability in patient responses to existing therapies. One promising approach involves targeting TRBV9-expressing T cells with monoclonal antibodies and bispecific T-cell engagers, which may minimize off-target effects. These therapies have shown favorable outcomes in clinical trials, particularly for HLA-B27-positive patients.
- ▪Current treatments for axSpA include nonsteroidal anti-inflammatory drugs and various inhibitors, but responses can vary significantly among patients.
- ▪A new monoclonal antibody targeting TRBV9 showed superior response rates in a phase 2 trial compared to placebo.
- ▪Bispecific T-cell engagers represent a novel approach that may lead to deeper clinical remissions by eliminating autoreactive T cells.
Opening excerpt (first ~120 words) tap to expand
TORONTO — Currently available drugs to treat patients with axial spondyloarthritis (axSpA) are generally effective for symptom control, and many also for structural protection, but not everyone responds and new agents are being developed to help fill the treatment gap.Akihiro Nakamura, MD, PhDThat was the message from Akihiro Nakamura, MD, PhD, assistant professor in the Department of Medicine at Queen’s University, Kingston, Ontario, Canada, in his presentation during the Spondyloarthritis Research and Treatment Network (SPARTAN) 2026 Annual Meeting.Nonsteroidal anti-inflammatory drugs, TNF inhibitors, interleukin (IL)-17 inhibitors, and JAK inhibitors primarily target specific released cytokines (such as TNF and IL-17A/F) or intracellular signaling molecules (JAKs), thereby broadly…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
